Glenn J Rapsinski
Overview
Explore the profile of Glenn J Rapsinski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
386
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rapsinski G, Rokes A, Van Tyne D, Cooper V
Microbiol Spectr
. 2025 Feb;
13(3):e0231224.
PMID: 39932323
Importance: Antibiotic resistance is a significant challenge for physicians trying to treat infections. The development of novel antibiotics to treat resistant infections has not been prioritized for decades, limiting treatment...
2.
Hilliam Y, Armbruster C, Rapsinski G, Marshall C, Moore J, Koirala J, et al.
Microbiol Spectr
. 2024 Jun;
12(8):e0078724.
PMID: 38916354
Elexacaftor/tezacaftor/ivacaftor (ETI) therapy has revolutionized the treatment of cystic fibrosis (CF) for most affected individuals but the effects of treatment on sinus microbiota are still unknown. Changes to the airway...
3.
Rapsinski G, Michaels L, Hill M, Yarrington K, Haas A, DAmico E, et al.
PLoS Pathog
. 2024 May;
20(5):e1011453.
PMID: 38820569
Mucosa-associated biofilms are associated with many human disease states, but the host mechanisms promoting biofilm remain unclear. In chronic respiratory diseases like cystic fibrosis (CF), Pseudomonas aeruginosa establishes chronic infection...
4.
Atteih S, Armbruster C, Hilliam Y, Rapsinski G, Bhusal J, Krainz L, et al.
Pediatr Pulmonol
. 2024 Feb;
59(5):1266-1273.
PMID: 38353361
Background: While the widespread initiation of elexacaftor/tezacaftor/ivacaftor (ETI) has led to dramatic clinical improvements among persons with cystic fibrosis (pwCF), little is known about how ETI affects the respiratory mucosal...
5.
Rapsinski G, Freeman M, Haidar G, Belle S, Hasskamp J, Wheeler S
J Clin Virol Plus
. 2022 Mar;
1(3):100026.
PMID: 35262012
Background: Children infected with SARS-CoV-2 are often asymptomatic or have only mild symptoms, leading to underestimation of disease prevalence in symptom-based testing strategies. Objectives: This study sought to determine pediatric...
6.
Henry B, Benoit S, Lippi G, Sabalza M, Venkataraman I, Geisler D, et al.
Am J Clin Pathol
. 2021 Sep;
157(2):314-316.
PMID: 34480168
No abstract available.
7.
Geisler D, Freeman M, Rapsinski G, Wheeler S
Am J Clin Pathol
. 2021 Apr;
155(6):773-775.
PMID: 33899091
Objectives: Serologic assay performance studies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pediatric populations are lacking, and few seroprevalence studies have routinely incorporated orthogonal testing to improve accuracy....
8.
Freeman M, Rapsinski G, Zilla M, Wheeler S
J Pediatric Infect Dis Soc
. 2020 Oct;
10(4):426-431.
PMID: 33049042
Background: The burden of coronavirus disease 2019 (COVID-19) is poorly understood in pediatric patients due to frequent asymptomatic and mild presentations. Additionally, the disease prevalence in pediatric immunocompromised patients remains...
9.
Wilson R, Tursi S, Rapsinski G, Medeiros N, Le L, Kotredes K, et al.
PLoS Pathog
. 2019 Apr;
15(4):e1007745.
PMID: 31009517
The mechanisms by which the gut luminal environment is disturbed by the immune system to foster pathogenic bacterial growth and survival remain incompletely understood. Here, we show that STAT2 dependent...
10.
Rapsinski G, Makadia J, Bhanot N, Min Z
J Med Case Rep
. 2016 Oct;
10(1):275.
PMID: 27716406
Background: Gram-negative microorganisms are uncommon pathogens responsible for infective endocarditis. Pseudomonas mendocina, a Gram-negative water-borne and soil-borne bacterium, was first reported to cause human infection in 1992. Since then, it...